BIAF
NASDAQ · Biotechnology
Bioaffinity Technologies Inc
$0.85
+0.10 (+13.49%)
Income Statement
| FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|
| Revenue | 608.9K | 644.1K | 622.1K |
| Net Income | -195,635 | -204,930 | -154,699 |
| EPS | — | — | — |
| Profit Margin | -32.1% | -31.8% | -24.9% |
| Rev Growth | +18.5% | +20.2% | +21.8% |
Balance Sheet
| FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|
| Total Debt | 2.01M | 1.61M | 1.67M |
| Total Equity | 1.57M | 1.50M | 1.46M |
| D/E Ratio | 1.28 | 1.08 | 1.14 |
Cash Flow
| FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|
| EBITDA | -176,028 | -183,952 | -197,812 |
| Free Cash Flow | -119,784 | -113,422 | -103,605 |